Acute Lung Injury Market

USD 1.83 billion in 2026 to USD 3.65 billion by 2036 at a 7.1% CAGR.

• As per Fact.MR analysis, the acute lung injury market was valued at USD 1.71 billion in 2025.
• Demand will grow from USD 1.83 billion in 2026 to USD 3.65 billion by 2036.
• The forecast records a 7.1% CAGR from 2026 to 2036, reflecting the projected expansion of treatment demand and supportive respiratory care.

Source: Fact.MR analysis. Updated Oct 29, 2026

What are the defining numbers behind Acute Lung Injury Market growth?

USD 1.9 billion absolute opportunity between 2026 and 2036

• Demand Drivers in the Market
  • Rising burden of sepsis and severe infections has driven the market growth. Severe infections can trigger an excessive inflammatory response that damages lung tissue and may lead to acute respiratory distress syndrome (ARDS). The World Health Organization reported 48.9 million sepsis cases and 11 million sepsis-related deaths worldwide, based on data from 2020 [1] .
  • Increasing clinical research into targeted treatments expand the future treatment pipeline and create opportunities for new therapies if they demonstrate safety and efficacy and receive regulatory approval. ClinicalTrials.gov lists a recruiting Phase 2 trial of BTI-203 (recombinant human plasma gelsolin), sponsored by BioAegis Therapeutics, for moderate-to-severe ARDS associated with pneumonia or other infections. The trial record was updated on September 10, 2026, and evaluates the treatment alongside standard care [2].
  • High mortality associated with pneumonia and respiratory complications is supporting the market growth. Pneumonia is an important cause of severe lung injury and ARDS. According to the US Centers for Disease Control and Prevention (CDC), the United States recorded 41,627 pneumonia-related deaths in 2024. Severe pneumonia can progress to respiratory failure, requiring intensive care, oxygen therapy or mechanical ventilation [3].
• Key Segments Analyzed
  • By Treatment Type: Pharmacotherapy will account for 48.3% of the market in 2026. Drug-based treatment remains an important part of managing the underlying condition and associated complications.
  • By End-User: Hospitals will lead with a 62.7% share in 2026, reflecting the need for intensive monitoring and advanced respiratory support among severely affected patients.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, states, “Acute lung injury treatment requires coordinated clinical management rather than reliance on a single intervention. Pharmacotherapy, respiratory support and adjunctive measures serve different purposes according to patient severity and clinical circumstances.”
• Strategic Implications
  • Drug developers should demonstrate clinical benefit and acceptable safety profiles in clearly defined patient populations.
  • Hospitals need treatment protocols that coordinate pharmacotherapy with respiratory support and intensive monitoring.
  • Biotechnology companies must distinguish investigational candidates from approved therapies and substantiate claims with clinical evidence.
  • Healthcare providers need to select treatment approaches according to disease severity, patient characteristics and established clinical guidance.

Germany is set to record a 7.9% CAGR through 2036. Brazil is set to post 7.3%, followed by the USA at 6.6%. The UK is estimated to advance at 5.9%, while Japan is forecast at 5.2%.

Fact.MR finds that Pharmacotherapy leads Treatment Type at 48.3%, while Hospitals leads End-User at 62.7%.

Which Treatment Type dominates?

Pharmacotherapy is set to hold a 48.3% share in 2026.

Source: Fact.MR analysis. Updated Oct 29, 2026

Pharmacotherapy includes medicines used to address underlying causes, inflammation and complications associated with acute lung injury. The treatment selected depends on the patient's condition and the clinical evidence supporting its use. Mechanical ventilation provides respiratory support when oxygenation is inadequate, while adjunctive therapies complement the primary treatment plan. These approaches serve different clinical purposes and may be used together [4].

How does End-User shape demand?

Hospitals are likely to account for 62.7% of the market in 2026.

Source: Fact.MR analysis. Updated Oct 29, 2026

Hospitals provide intensive care facilities, ventilatory support and access to multidisciplinary clinical teams. These resources are important for patients with severe acute lung injury who need continuous monitoring. Specialty clinics may support selected follow-up and specialist services, while ambulatory surgical centers have a more limited role in managing severe acute respiratory failure. The residual share represents specialty clinics, ambulatory surgical centers and other settings combined.

Increasing demand for advanced respiratory support and new treatment research may support market growth, but clinical uncertainty and development costs remain important constraints.

Drivers Impact Analysis

Source: Fact.MR analysis. Updated Oct 29, 2026

Opportunity Impact Analysis

Source: Fact.MR analysis. Updated Oct 29, 2026

Restraints Impact Analysis

Source: Fact.MR analysis. Updated Oct 29, 2026

Source: Fact.MR analysis. Updated Oct 29, 2026

What supports Germany adoption?

7.9% CAGR, based on rising clinical needs associated with ARDS and continued demand for improved ICU diagnosis and treatment.

Germany's market outlook is linked to its hospital infrastructure and access to specialist respiratory and intensive care services. Management of severe acute lung injury requires coordinated clinical assessment and respiratory support. The uptake of new therapies will depend on clinical evidence, applicable authorization requirements and adoption within hospital treatment pathways.

How is Brazil developing acute lung injury treatment?

7.3% CAGR, supported by burden of severe respiratory infections.

Brazil's projected growth reflects the potential importance of improving access to intensive care and advanced respiratory support across its healthcare system. Differences in hospital resources and access to specialist services may affect treatment availability. The introduction of investigational medicines will also depend on clinical results and applicable regulatory authorization.

What supports United States adoption?

6.6% CAGR, driven by strong clinical research activity.

The USA is an important setting for clinical development of acute lung injury therapies. MiNK Therapeutics is advancing agenT-797 in a randomized Phase 2 study, while Edesa Biotech has reported Phase 3 results for its investigational ARDS candidate paridiprubart (EB05). These programs illustrate ongoing research into new treatment approaches, although investigational status and clinical outcomes must be distinguished from established standard care [5] [6].

How is the United Kingdom building adoption?

5.9% CAGR, shaped by Substantial hospital demand from respiratory illnesses.

The UK outlook depends on hospital-based respiratory care, access to critical care facilities and the use of evidence-based treatment protocols. Uptake of new therapies will depend on the strength of clinical evidence, regulatory decisions and decisions regarding access within the healthcare system. Research partnerships and participation in clinical trials may also contribute to the development of treatment options.

What supports Japan adoption?

5.2% CAGR, reflecting an ageing population, respiratory infection risks and ongoing research into acute lung injury.

Japan's projected market expansion is associated with the need to manage severe respiratory illness through hospital-based treatment and specialist monitoring. The potential uptake of novel therapies depends on evidence of safety and effectiveness, regulatory review and clinical suitability. Hospitals remain important settings for coordinating respiratory support and treatment of complications.

Fact.MR's competitive overview covers biotechnology companies developing investigational therapies for acute lung injury and acute respiratory distress syndrome (ARDS). MiNK Therapeutics, Edesa Biotech, Aqualung Therapeutics, Direct Biologics, Citius Pharmaceuticals and Chrysalis BioTherapeutics have identifiable research or development programs relevant to acute lung injury or ARDS.

Edesa Biotech is developing paridiprubart (EB05), a monoclonal antibody targeting TLR4-mediated inflammatory signaling. The company has reported Phase 3 study results in hospitalized ARDS patients. Aqualung Therapeutics is developing ALT-100, a monoclonal antibody targeting eNAMPT-related inflammatory signaling, for ARDS and ventilator-induced lung injury. Direct Biologics is developing DB-2Q, an investigational secretome-based candidate for ARDS [7] [8].

Citius Pharmaceuticals is investigating induced mesenchymal stem cells for ARDS, with its published program describing preclinical development. Chrysalis BioTherapeutics is developing TP508 (Chrysalin), a regenerative peptide intended for ARDS and related lung injury.

Commercial competition in this market depends on clinical evidence, regulatory progress, manufacturing capability and access to hospital-based treatment pathways. These companies should be profiled as relevant developers rather than treated as six established commercial suppliers of approved acute lung injury medicines.

Key companies include MiNK Therapeutics; Edesa Biotech Inc.; Aqualung Therapeutics Corp.; Direct Biologics; Citius Pharmaceuticals; and Chrysalis BioTherapeutics.

• MiNK Therapeutics Edesa Biotech Inc.
• Aqualung Therapeutics Corp.
• Direct Biologics
• Citius Pharmaceuticals
• Chrysalis BioTherapeutics

• [1] World Health Organization. (2024, May 3). Sepsis.
• [2] BioAegis Therapeutics Inc. (2026, September 10). Rhu-pGSN for acute respiratory distress syndrome (ARDS) (ClinicalTrials.gov Identifier NCT05947955). ClinicalTrials.gov.
• [3] National Center for Health Statistics. (n.d.). Pneumonia. Centers for Disease Control and Prevention.
• [4] Qadir, N., Sahetya, S., Munshi, L., Summers, C., Abrams, D., Beitler, J., Bellani, G., Brower, R. G., Burry, L., Chen, J.-T., Hodgson, C., Hough, C. L., Lamontagne, F., Law, A., Papazian, L., Pham, T., Rubin, E., Siuba, M., Telias, I., … Fan, E. (2024). An update on management of adult patients with acute respiratory distress syndrome: An official American Thoracic Society clinical practice guideline. American Journal of Respiratory and Critical Care Medicine, 209(1), 24–36.
• [5] MiNK Therapeutics, Inc. (2026, August 13). MiNK Therapeutics reports second quarter 2026 financial results and reports observations from randomized Phase 2 trial of agenT-797 in acute lung injury.
• [6] Edesa Biotech, Inc. (2026, January). Clinical pipeline.
• [7] Aqualung Therapeutics. (n.d.). Our science.
• [8] Direct Biologics. (n.d.). Our pipeline.

• The report describes how acute lung injury treatment demand is distributed across pharmacotherapy, mechanical ventilation and adjunctive therapies.
• Segment analysis compares the specified treatment categories and the 2026 pharmacotherapy share.
• End-user analysis examines hospitals, specialty clinics, ambulatory surgical centers and other care settings.
• Country analysis discusses Germany, Brazil, the USA, the UK and Japan alongside the growth forecasts.
• The competitive overview profiles six companies with relevant acute lung injury or ARDS development programs.

The market covers pharmacological treatments and supportive interventions used in the management of acute lung injury, including relevant ARDS treatment approaches. It examines the role of respiratory support, adjunctive care and hospital-based treatment, alongside the development of investigational therapies intended to address inflammation and lung injury.

What is included in the scope?

Included categories comprise medicines used in acute lung injury management, mechanical ventilation and adjunctive therapies.

The end-user analysis covers hospitals, specialty clinics, ambulatory surgical centers and other settings. The competitive assessment includes relevant therapeutic candidates in clinical or preclinical development, with their development status identified separately from approved treatments.

What is excluded from the scope?

The analysis excludes treatments unrelated to acute lung injury and respiratory distress.

General respiratory medicines are outside the defined scope when they have no relevant application to acute lung injury management. Revenue from unrelated oncology, dermatology and other non-respiratory programs of the profiled companies is also excluded. Investigational products are not classified as approved medicines.

How Was the Analysis Built?

The analysis draws on 120+ sources, 35+ company portfolios, 25+ countries, and more than 20 industry interviews.

• Primary Research: Primary research includes discussions with manufacturers, service providers, technology developers, distributors, end users, and subject-matter experts. These conversations examine purchasing priorities, product adoption, operational challenges, approval requirements, competitive positioning, and the factors that influence wider market acceptance.
• Desk Research: Desk research covers government statistics, regulatory publications, company filings, trade data, technical studies, industry associations, standards, public policy, and other authoritative sources. Every source used in the analysis is documented in the bibliography.
• Market Sizing and Forecasting: Market estimates combine historical performance, demand indicators, pricing and volume trends, segment shares, company participation, country-level growth, adoption patterns, investment activity, and barriers to market expansion.
• Data Validation and Update Cycle: Findings are validated by comparing primary interviews with public data, company activity, regulatory changes, trade patterns, and industry developments. Regular updates review new product launches, capacity changes, partnerships, approvals, and shifts in commercial adoption.